Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence

Condition(s) targeted: Adult Attention Deficit Hyperactivity Disorder; Cocaine Dependence

Intervention: Placebo (Drug); Adderall-XR (Drug); Adderall-XR (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: New York State Psychiatric Institute

Official(s) and/or principal investigator(s):
Frances R Levin, MD, Principal Investigator, Affiliation: Columbia University
John Grabowski, Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute

Overall contact:
Amy Mahony, MA, Phone: 212-740-7351, Email: mahonya@nyspi.columbia.edu

The proposed protocol is a 3 group double-blind, placebo-controlled outpatient study of the safety and efficacy of Adderall-XR (ER-MAS) in the treatment of comorbid ADHD and cocaine dependence. Since this medication has independently shown promise in helping with ADHD and cocaine abuse, we are proposing that it may be successful in the treatment of comorbid ADHD and cocaine abuse. We plan to enroll 75 subjects in a 14-week trial. The primary objectives of the study are to determine the efficacy of ER-MAS in promoting cocaine abstinence and improvement in ADHD symptomology among cocaine-dependent patients with comorbid ADHD.

Official title: A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

cocaine urine toxicology results

ADHD symptoms based on ADHD Rating Scale

Secondary outcome: ADHD symptoms based on CGI

Detailed description: Specific Aim 1: To determine the efficacy of ER-MAS in promoting cocaine abstinence and ADHD improvement among comorbid ADHD and cocaine-dependent patients.

Primary Hypothesis: benzoylecgonine positive urine screens will decrease with greatest to least reductions from 80mg>60mg>PBO (placebo).

Hypothesis 2: ADHD-Rating Scale will decrease with greatest to least reductions from 80mg>60mg>PBO.

Specific Aim 2: To determine the effect of ER-MAS on improving general functioning and impulsivity among comorbid ADHD and cocaine-dependent patients.

Hypothesis 4: There will be greater improved CGI (clinical global impression scale) scores in participants receiving d-AMPH (d-amphetamine) compared to PBO.

Hypothesis 5: ER-MAS will decrease impulsivity as measured by several self-report (Barratts Impulsivity Scale) and behavioral measures (Card Sort, IMT (immediate memory task), DMT (delayed memory task), BART) compared to PBO.

This 14-week, three arm (two medication doses versus PBO), prospective, parallel groups, randomized PBO-controlled trial with a lead-in as well as medication run-up and run down weeks, will provide clear data on efficacy and safety for definitive Phase III trials, which if successful will lead to improved treatment for A-ADHD/S-SUD.

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Men and women between the ages of 18-60 who meet DSM-IV criteria for current cocaine dependence and adult ADHD (DSM-IV-TR).

2. Used cocaine at least four days in the past month

3. Must have a Body Mass Index (BMI) > 18 kg/m2

4. Alcohol Breathalyzer (BraC) at consent of < 0. 04%

5. Individuals must be capable of giving informed consent and capable of complying with study procedures.

6. Women of child bearing age will be included in the study provided that they are not pregnant, based on the results of a blood pregnancy test drawn at the time of screening. They must also agree to use a method of contraception with proven efficacy and agree not to become pregnant during the study. To confirm this, blood pregnancy tests will be repeated monthly. Women will be provided a full explanation of the potential dangers of pregnancy while on the study medication. If a woman becomes pregnant, the study medication will be discontinued.

Exclusion Criteria:

1. Meets DSM-IV-TR criteria for bipolar disorder, schizophrenia or any psychotic disorder other than transient psychosis due to drug abuse.

2. Individuals with any current Axis I psychiatric disorder as defined by DSM-IV-TR supported by the SCID-I/P that in the investigator's judgment are unstable or would be disrupted by study medication or are likely to require pharmacotherapy during the study period.

3. Individuals with current major depressive disorder. However,individuals who are currently stable on a psychotropic medication for three months with a HAM-D <14 may be included.

4. Individuals physiologically dependent on any other drugs (excluding nicotine or cannabis) which require medical intervention.

5. Individuals with current suicidal risk.

6. Individuals with coronary vascular disease as indicated by history or suspected by abnormal ECG, cardiac symptoms, fainting, open-heart surgery and/or arrhythmia, and family history of ventricular tachycardia/sudden death.

7. Unstable physical disorders which might make participation hazardous such as uncontrolled hypertension (SBP > 140, DBP> 90, or HR > 100 when sitting quietly), acute hepatitis (patients with chronic mildly elevated transaminases < 3x upper limit of normal are acceptable), or uncontrolled diabetes.

8. Individuals with a history of seizures

9. History of allergic reaction to candidate medication (amphetamine and/or ER-MAS).

10. Women who are pregnant or nursing.

11. History of failure to respond to a previous adequate trial of the candidate medication for cocaine dependence

12. Individuals who are legally mandated (e. g., to avoid incarceration, monetary or other penalties, etc.) to participate in substance abuse treatment program

13. History of glaucoma

14. Individuals who report use of MAOI within 14 days of study start

Amy Mahony, MA, Phone: 212-740-7351, Email: mahonya@nyspi.columbia.edu

Ambulatory Research Center/Fairview University Psychiatry Dept, Minneapolis, Minnesota 55454, United States; Recruiting
David Babb, Phone: 612-627-4824, Email: babbx001@umn.edu
Carla Amundson, M.A., Email: CMAMUN01@smumn.edu
John Grabowski, PhD, Principal Investigator

STARS, New York, New York 10032, United States; Recruiting
Amy Mahony, MA, Phone: 212-740-7351, Email: mahonya@pi.cpmc.columbia.edu
Daniel Brooks, MA, Phone: 212-740-3205, Email: brooksd@pi.cpmc.columbia.edu
Frances R Levin, MD, Principal Investigator

Substance Treatment and Research Service of Columbia University

Starting date: December 2007
Last updated: January 28, 2013